Source:http://linkedlifedata.com/resource/pubmed/id/10901605
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2000-7-28
|
pubmed:abstractText |
Allogeneic stem cell transplantation (allo SCT) is now frequently performed for the treatment of haematological malignancies and aplastic anaemia. However, graft-versus-host disease (GVHD) is still the major complication after allo SCT, producing immune deficiency, infection, organ damage and, occasionally, patient death. The antigen-specific signal mediated by the T-cell receptor (TCR) is essential for activation of T-cells; however, additional co-stimulatory signals are required for complete T-cell activation. Therefore, blocking strategies of co-stimulatory signals have been evaluated as targets of therapeutic intervention for GVHD after allo SCT. In a mouse bone-marrow transplantation (BMT) model, the administration of CTLA4-Ig, which blocks the interaction of CD28 on T-cells and B7 molecules on antigen-presenting cells (APCs), can prolong survival of allo BMT recipients, although this effect was not complete. In addition, the anti-CD40L (CD154) monoclonal antibody (mAb), which can interfere with the interaction of CD154 on T-cells and CD40 on APCs, can induce long-term graft survival in the murine model. Combined administration of CTLA4-Ig and anti-CD40L mAb can prevent allograft rejection in primates. Therefore, it seems the most powerful method to prevent the alloimmune response in vivo. The Fas/Fas ligand pathway is also involved in pathogenesis of GVHD. Anti-FasL mAb can reduce the mortality of GVHD and improve intestinal lesions. Recently, it was reported that donor bone marrow treated ex vivo using CTLA4-Ig reconstituted haematopoiesis in vivo with a relatively low risk of GVHD in human allo BMT. Therefore, selective blocking strategies for T-cell co-signalling might be useful for the prevention of GVHD in human allo SCT.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0939-5555
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
79
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
283-90
|
pubmed:dateRevised |
2005-11-16
|
pubmed:meshHeading |
pubmed-meshheading:10901605-Animals,
pubmed-meshheading:10901605-Antigen Presentation,
pubmed-meshheading:10901605-Antigens, CD28,
pubmed-meshheading:10901605-Antigens, CD80,
pubmed-meshheading:10901605-Bone Marrow Transplantation,
pubmed-meshheading:10901605-Graft vs Host Disease,
pubmed-meshheading:10901605-Humans,
pubmed-meshheading:10901605-Lymphocyte Activation,
pubmed-meshheading:10901605-Mice,
pubmed-meshheading:10901605-Receptors, Antigen, T-Cell,
pubmed-meshheading:10901605-T-Lymphocytes
|
pubmed:year |
2000
|
pubmed:articleTitle |
T-cell co-signalling molecules in graft-versus-host disease.
|
pubmed:affiliation |
Department of Haematology and Oncology, Hokkaido University School of Medicine, Sapporo, Japan.
|
pubmed:publicationType |
Journal Article,
Review
|